Abstract
BackgroundChimeric antigen receptor (CAR)-T cell immunotherapy has modified the concept of treatment in hematological malignancies. In comparison with pediatric patients, where responses are maintained over many years, older patients, such...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have